The role of M3-muscarinic receptor signalling in insulin secretion by Kong, Kok Choi & Tobin, Andrew
www.landesbioscience.com Communicative & Integrative Biology 489
Communicative & Integrative Biology 4:4, 489-491; July/August 2011; ©2011 Landes Bioscience
ArtICLe Addendum
Addendum to: Kong KC, Butcher AJ, McWilliams 
P, Jones D, Wess J, Hamdan FF, et al. M3-
muscarinic receptor promotes insulin release via 
receptor phosphorylation/arrestin-dependent 
activation of protein kinase D1. Proc Natl Acad 
Sci USA 2010; 107:21181–6; PMID: 21078968; DOI: 
10.1073/pnas.1011651107.
Key words: M
3
-muscarinic receptor, 
insulin secretion, glucose homeostasis, 
protein kinase D1, ankyrin-B, RGS4, 
NALCN, biased ligands
Submitted: 04/04/11
Accepted: 04/04/11
DOI: 10.4161/cib.4.4.15716
*Correspondence to: Andrew B. Tobin;  
Email: tba@le.ac.uk
Recently, M3-muscarinic receptor (M3R) has been identified as the 
bona fide receptor responsible for the 
cholinergic regulation of glucose-induced 
insulin release. The molecular mecha-
nisms of such regulation have also begun 
to be unravelled. These include the con-
ventional G protein-dependent pathways 
involving calcium mobilization and acti-
vation of protein kinase C. In addition, 
recent studies also provided evidence for 
G protein-independent pathways in the 
regulation of insulin secretion by M3R. 
These include phosphorylation/arrestin-
dependent activation of protein kinase 
D1, Src family kinase-dependent activa-
tion of the sodium channel NALCN and 
the involvement of regulator of G protein 
signaling (RGS)-4. Time has now come 
to extend these studies which were done 
mainly in rodents to human and explore 
the potential for targeting such pathways 
at different levels for the treatment of 
diseases with impaired insulin secretion 
such as type II diabetes.
Insulin secretion by β cells of the islets of 
Langerhans in the pancreas is a process 
tightly regulated by glucose and other cir-
culating nutrients. It is also modulated by 
many other factors, including hormones 
and neurotransmitters. One of the most 
prominent of these regulatory mecha-
nisms is mediated by acetycholine (Ach) 
originating from the parasympathetic 
cholinergic input.1,2 Although choliner-
gic regulation of insulin release has been 
known for many years, the mechanism 
of regulation and in particular the iden-
tity of the subtype of cholinergic receptor 
responsible for this regulation has only 
recently been established. There are five 
cholingeric muscarinic receptor subtypes 
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(M
1
–M
5
) and the work of Gautam and 
colleagues using transgenic and gene 
knockout technology have determined 
that the M
3
-muscarinic receptor (M3R) is 
the bona fide acetylcholine receptor that is 
responsible for enhancing glucose-depen-
dent insulin release in β cells.3
Molecular Mechanisms  
for M3R-Mediated Insulin  
Secretion
The mechanism by which M3R regulates 
insulin release was thought to be primar-
ily via G-protein depending signaling 
to the calcium and PKC pathways. As a 
prototypical G
q/11
-coupled receptor, acti-
vation of M3R induces the hydrolysis of 
membrane phospholipid phosphatidylino-
sitol-4,5-biphosphate (PIP
2
), catalyzed by 
phospholipase C (PLC). This generates 
two second messengers, inositol-1,4,5-
trisphosphate (IP
3
) and diacylglycerol 
(DAG). IP
3
 in turn mobilizes calcium 
from the IP
3
-sensitive stores while DAG 
activates PKC. Both of these pathways 
have been thought to play an important 
role in M3R-mediated insulin secretion.1
However, recent molecular and genetic 
studies have pointed to further mecha-
nisms. In particular, sustained insulin 
release associated with the enteric phase 
appears to be mediated by a process that is 
independent of G-protein signaling. This 
is evidenced by studies from our laboratory 
and others which demonstrated that pro-
tein kinase D1 (PKD1) as one of the key 
components by which M3R regulates glu-
cose-dependent insulin release.4,5 PKD1 
is activated by the phosphorylated form 
of the M3R via a G-protein-independent, 
β-arrestin-dependent process that results 
in secretary vesicle priming.4 In addition, 
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over a decade ago.9 Ahren and colleagues 
demonstrated that the non-specific mus-
carinic receptor agonists, carbachol, when 
administered intravenously, not only 
potentiated glucose-stimulated insulin 
secretion in mice fed with either a con-
trol or a high-fat diet, but also normalized 
glucose-stimulated insulin secretion and 
glucose tolerance in mice subjected to a 
high-fat diet.9 This study led to the pro-
posal that the development of islet-specific 
muscarinic agonists, with lesser general 
muscarinic activity, might be a feasible 
target to improve insulin secretion in type 
II diabetes.9
This proposal has only been put to 
vigorous investigation in recent years. 
After identifying M3R as the bona fide 
acetylcholine receptor that is responsible 
for enhancing glucose-dependent insulin 
release, Gautam and colleagues performed 
a series of studies which concluded with 
the generation of transgenic mice that 
express a constitutively active mutant of 
M3R specifically in pancreatic β cells 
in order to mimick the effects of a drug 
belongs to the four domain ion channel 
family. M3R has been shown to activate 
this channel in the model pancreatic β cell 
line, MIN-6, via the Src family of tyrosine 
kinases (SFKs).7 In addition, one more 
piece of the jigsaw puzzle is the regula-
tors of G-protein signaling protein, RGS4. 
Ruiz de Azua and colleagues have dem-
onstrated that RGS4 negatively modulate 
M3R-mediated insulin secretion in β cells 
due to its selective inhibition of M3R sig-
naling in β cells.8
Hence, there appears to be a number 
of possible in vivo mechanisms that act in 
concert to regulate the early and late phases 
of insulin secretion by M3R (Fig. 1).
Physiological Implication  
of M3R-Mediated Insulin Secretion
Though the cellular mechanisms by 
which the M3R mediates insulin release 
have only recently been elucidated, the 
in vivo effects of muscarinic receptor 
agonists in regulating glucose-stimulated 
insulin secretion have been first examined 
M3R has also been shown to stimulate 
insulin release by inhibiting the mitogen 
activated protein kinase p38δ activity, 
which has inhibitory effects on PKD1 in 
β cells.5
Other studies have, however, returned 
to the importance of calcium signaling. 
Healy and colleagues demonstrated that 
the expression level of IP
3
-receptors in β 
cells is crucial for M3R-mediated insulin 
release.6 Binding of the adaptor protein 
ankyrin-B to the IP
3
-receptors in β cells 
stabilizes the receptors and thus enhances 
the calcium signal in the cells.6 Pancreatic 
islets from heterozygous ankyrin-B mutant 
(ankB+/-) mice exhibited a reduction in 
both basal and carbachol-stimulated 
intracellular calcium release,6 suggesting 
that the IP
3
-receptor is stabilized in the 
open state.
In addition, the sodium channel desig-
nated NALCN, which is short for sodium 
leak channel non-selective, has also been 
demonstrated to play a role in M3R-
mediated insulin release.7 This channel, 
formerly named Rb21 then VGCNL1, 
Figure 1. the possible mechanisms of m3-muscarinic receptor (m3r)-mediated insulin secretion. Conventional studies have provided evidence that 
the transient, early phase of insulin secretion is mediated by m3r via G protein-dependent signaling that results in increase in intracellular calcium 
and activation of protein kinase C.1 recent studies have shown that the sustained, late phase of insulin secretion is enhanced by m3r via G protein-
independent pathways which requires receptor phosphorylation/arrestin-dependent signaling to PKd1 4 and Src family tyrosine kinases signaling to 
sodium channel nALCn.7
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The next step forward is to determine 
the effectiveness of β cell M3Rs and/
or downstream signaling components 
as drug targets for the treatment of type 
II diabetes and in particular it will be 
important to extend the studies that have 
been largely conducted in rodent models 
to humans.
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pathways would be of therapeutic benefit.4 
The effectiveness of such biased-agonists 
has been demonstrated in the case of the 
β-adrenoceptor agonist carvedilol for the 
treatment of heart disease. The therapeu-
tic efficacy of carvedilol in the treatment 
of heart disease has been attributable to 
the fact that this ligand can direct signal-
ing of the β-adrenoceptor to the arrestin-
dependent pathways.13 Similar biased 
ligands that direct signaling of the M3R 
via arrestin signaling would be expected 
to potentiate insulin release at β-islets in a 
manner that results in reduced side effects 
since G-protein-dependent calcium sig-
naling would be minimized.
It is also possible to target the sig-
naling proteins downstream of M3Rs. 
In particular, PKD1 and ankyrin-B are 
two potentially promising targets as evi-
denced by both in vitro and in vivo data. 
Though homozygous PKD1-knockout 
(PKD1-/-) mice are embryonic lethal,14 
deletion of PKD1 in INS1 insulinoma 
cells completely abolished the insulin 
release induced by glucose and carba-
chol.5 siRNA-knockdown of PKD1 in 
mouse islets also impaired the M3R-
mediated augmentation of glucose-
induced insulin secretion.4 Carbachol 
augmentation of glucose-induced insulin 
secretion was significantly impaired in 
islets prepared from ankB+/- mice or in 
rat islets following siRNA-knockdown 
of ankyrin-B.6 In addition, ankB+/- mice 
exhibited hyperglycemia after oral inges-
tion of glucose and the R1788W muta-
tion of ankyrin-B impaired its function 
in islets and is associated with type II 
diabetes in Caucasians and Hispanics.6 
These studies demonstrate that targeting 
the signaling pathways downstream of 
the M3R can effectively modulate insu-
lin release.
Concluding Remarks
It is now an exciting time to put these 
hypotheses to test and devise further 
therapeutic treatments for type II diabe-
tes. Though much is now known about 
the M3R-mediated insulin secretion 
pathway, much still needs to be done. 
that chronically activates β cell M3Rs.10 
These mutant mice exhibited markedly 
improved glucose tolerance and increased 
serum insulin levels as well as resistance 
to diet-induced glucose intolerance and 
hyperglycemia.10 These studies strongly 
supported the hypothesis that chronic, 
sustained activation of β cell M3Rs might 
produce beneficial effects to glucose 
homeostasis, and further established the 
therapeutic potential for M3R selective 
agonists for the treatment of type II diabe-
tes. However, due to the multiple periph-
eral actions of M3Rs such as smooth 
muscle contraction and saliva secretion, 
the use of such agonists may be limited by 
their possible side effects.
Clinical Targeting of M3R  
Signaling in Insulin Secretion  
in Disease
The notion of targeting M3Rs in disorders 
where insulin secretion is de-regulated 
such as type II diabetes runs into the dif-
ficulty of developing ligands that are selec-
tive to the M3R subtype and that do not 
also interact with the other muscarinic 
receptor subtypes, namely M1, M2, M4 
and M5. The problems associated with 
developing subtype selective ligands cen-
tre on the fact that the acetylcholine bind-
ing site on muscarinic receptors is very 
conserved between the five receptor sub-
types. However, hope for subtype-selec-
tive targeting of the muscarinic receptors 
has recently emerged with the discovery of 
ligands that interact with allosteric sites on 
the receptors.11,12 These so called allosteric 
modulators target variant regions of the 
receptor and therefore can show subtype 
selectivity. With the use of positive allo-
steric modulators (PAMs), which increase 
the affinity and/or efficacy of acetylcho-
line to the M3R, the effects of the natu-
ral ligand acetylcholine can be enhanced 
selectively at the M3R.
In addition to allosteric modulators 
the discovery that the M3R can potenti-
ate insulin release through an arrestin-
dependent mechanism suggests that 
biased-agonists that direct muscarinic 
receptor signaling to arrestin-dependent 
